Summit Therapeutics Inc.
SMMT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $12,826 | $1,617 | $822 | $248 |
| - Cash | $105 | $71 | $349 | $72 |
| + Debt | $7 | $106 | $519 | $3 |
| Enterprise Value | $12,728 | $1,652 | $992 | $179 |
| Revenue | $0 | $0 | $1 | $2 |
| % Growth | – | -100% | -61.1% | – |
| Gross Profit | -$15 | -$2 | -$2 | $2 |
| % Margin | – | – | -257% | 100% |
| EBITDA | -$213 | -$69 | -$73 | -$86 |
| % Margin | – | – | -10,381.7% | -4,748.8% |
| Net Income | -$221 | -$615 | -$79 | -$89 |
| % Margin | – | – | -11,185.9% | -4,897.8% |
| EPS Diluted | -0.31 | -0.99 | -0.38 | -0.96 |
| % Growth | 68.7% | -160.5% | 60.4% | – |
| Operating Cash Flow | -$142 | -$77 | -$42 | -$73 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$142 | -$77 | -$42 | -$73 |